The Liver X Receptor Is Upregulated in Monocyte-Derived Macrophages and Modulates Inflammatory Cytokines Based on LXRα Polymorphism

Figure 6

Expression of proinflammatory cytokines after treatment with liver X receptor (LXR) agonist in peripheral blood mononuclear cell- (PBMC-) derived macrophages of patients with SLE according to the LXRα -1830 T > C genotypes. mRNA expression of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2), and interferon-γ (IFN-γ) was measured by quantitative real-time PCR. (a) Treatment with LXR agonists. (b) and (c) Treatment with TLR7 or TLR9 inhibitors and LXR agonists in human TLR7/8 agonist- (CL097-) or TLR9- (ODN-) stimulated PBMC-derived macrophages from SLE patients with the LXRα -1830 TT (b) and TC (c) genotype. (d) Protein levels of LXRα and ABCA1 according to the LXRα -1830 TT and TC genotype after treatment with TLR7 or TLR9 inhibitors. For immunoblot analysis of LXRα and ABCA1, total cellular proteins were extracted from PBMCs of SLE patients with the genotypes -1830 TT or TC. Data are shown from three independent experiments. Values are the means and SD. vs. controls.

(a)

(b)

(c)

(d)